Health Care [ 12/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.
The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity.
Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 29, 25 | -0.27 Increased by +5.55% | -0.24 Decreased by -14.12% |
| Dec 31, 24 | -0.16 Increased by +40.67% | -0.23 Increased by +29.33% |
| Nov 8, 24 | -0.24 Increased by +33.33% | -0.26 Increased by +7.69% |
| Aug 6, 24 | -0.26 Increased by +29.73% | -0.32 Increased by +18.75% |
| May 6, 24 | -0.29 Increased by +12.12% | -0.20 Decreased by -45.00% |
| Mar 20, 24 | -0.27 Increased by +22.86% | -0.31 Increased by +12.90% |
| Nov 8, 23 | -0.36 Decreased by -9.09% | -0.37 Increased by +2.70% |
| Aug 11, 23 | -0.37 Decreased by -19.35% | -0.40 Increased by +7.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 172.00 K Increased by +N/A% | -7.26 M Increased by +2.93% | Decreased by -4.22 K% Decreased by N/A% |
| Dec 31, 24 | 1.03 M Decreased by -62.62% | -8.95 M Decreased by -26.05% | Decreased by -870.33% Decreased by -237.19% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -6.78 M Increased by +26.25% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -6.80 M Increased by +26.85% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -7.48 M Increased by +10.62% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.75 M Increased by +N/A% | -7.10 M Increased by +59.07% | Decreased by -258.11% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.20 M Increased by +43.26% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -9.30 M Increased by +41.73% | Decreased by N/A% Decreased by N/A% |